Tag - Corbus Pharmaceuticals

Inside the small Norwood biotech that’s making investors swoon

The top-performing public biotech in Massachusetts over the past year is located in a nondescript brick building with no signage, located along a stretch of highway in Norwood that is better known for its car dealerships than drug developers.
Investors in Corbus Pharmaceuticals don’t much seem to mind. The 3-year-old company, situated some 25 miles south of Cambridge and the bustling biotech hub of Kendall Square, has seen its stock price increase more than 400 percent since March 2016, putting […]

Corbus Pharmaceuticals to Present Gene Expression Data from Recent Phase 2 Systemic Sclerosis Study Demonstrating JBT-101 Inhibits Inflammation and Fibrosis Pathways

Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), a clinical stage drug development company targeting rare, chronic, serious inflammatory and fibrotic diseases, announced today that Michael L. Whitfield, Ph.D., Professor of Molecular and Systems Biology, Dartmouth Geisel School of Medicine and Scientific Founder of Celdara Medical, LLC, will present data demonstrating JBT-101 treatment of systemic sclerosis patients inhibits gene expression of key regulatory proteins in molecular pathways associated with activating inflammation and fibrosis, while increasing gene expression […]

Corbus Pharmaceuticals to Present at the Cowen and Company 37th Annual Health Care Conference

Corbus Pharmaceuticals Holdings, Inc., a clinical stage drug development company targeting rare, chronic, serious inflammatory and fibrotic diseases, announced today that Yuval Cohen, Ph.D., Chief Executive Officer, will present at the Cowen and Company 37th Annual Health Care Conference on Wednesday, March 8 at 10:40 a.m. ET in Boston, MA. Read more >>

Corbus Pharmaceuticals Receives Orphan Designation for JBT-101 for the Treatment of Systemic Sclerosis in the European Union

Corbus Pharmaceuticals Holdings, Inc. (CRBP) (“Corbus” or the “Company”), a clinical stage drug development company targeting rare, chronic, serious inflammatory and fibrotic diseases, announced today that the European Commission has granted Orphan Designation in the European Union (“EU”) for the Company’s novel synthetic oral endocannabinoid-mimetic drug, JBT-101 (“Resunab”) for the treatment of systemic sclerosis. Read more >>

Why Corbus Pharmaceuticals Holdings, Inc. Stock Rocketed 412% Upwards in 2016

Shares of Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) thrilled investors with a 412.1% gain last year, according todata from S&P Global Market Intelligence Opens a New Window. . Positive mid-stage clinical trial results for its lead drug, Resunab, lifted the stock and ignited hope for further expansion in the future. Read more >>

Shares Bringing Holiday Cheer For Investors: Corbus Pharmaceuticals Holdings, Inc.

Shares of Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) have climbed in the previous month. During that time period, shares are up 6.88% which has provided some nice profits for investors who may be looking to take advantage of the recent gains. Focusing in on the past five trading days, shares have changed 4.27%. Year-to-date, the stock has performed 418.18%. Read more >>

Top Earnings Report to Watch for: Corbus Pharmaceuticals Holdings, Inc.

Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) is trading up 726.73% versus 12-month low of 1.01 and stands -22.54% lower from its 1-year peak of $10.78. The consensus price target (PT) of $17.00 means that the market expects Company shares to increase by 101.2% in the short run. The sell-side target prices range from $12 to $20. In the last month the stock has moved in price 5.03%, with a one year change of 412.27%. The last trading session volume compares […]

Two Biotech Stocks Are Just So Hot Right Now (Corbus Pharmaceuticals Holdings, Inc.)

On November 14, 2016 Corbus Pharmaceuticals Holdings, Inc. (CRBP) announced positive topline results from its Phase 2 study evaluating Resunab (“JBT-101”) for the treatment of diffuse cutaneous systemic sclerosis (“systemic sclerosis”). JBT-101 out-performed placebo in the American College of Rheumatology (ACR) Combined Response Index in diffuse cutaneous Systemic Sclerosis (CRISS) score, reaching 33% at week 16, versus 0% for placebo. Read more >>